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ABSTRACT
Introduction: The recent CONCEPT study
showed that 800 mg/day of pharmaceutical-
grade chondroitin sulfate (CS) was superior to
placebo and similar to celecoxib in reducing
pain and improving function over 6 months in
patients with symptomatic knee osteoarthritis
(OA). We investigate, in the present study,
whether a responder profile to CS could be
defined (i.e., to determine a patient’s profile
with the best response to treatment).
Methods: Subjects from the CS group of the
CONCEPT study were included in the present
analysis. Within the CS group, various sub-
groups were created on the basis of different
categories of age, sex, body mass index, Kellgren
and Lawrence grade, age since the beginning of
OA, and baseline level of pain (i.e., VAS) or
function (i.e., Lequesne index). The
nonparametric Kruskal–Wallis (KW) test was
applied to compare the VAS pain/Lequesne
index evolutions between the subgroups, and
the Dwass, Steel, Critchlow, Fligner (DSCF)
procedure was used to compute multiple com-
parisons. The impact of various covariates on
the VAS pain/Lequesne index evolution was
assessed by means of multiple regression.
Results: Across all analyses, the probability of
response to CS treatment was significantly
associated with the duration between the date
of diagnosis and the initiation of treatment. In
other words, the shorter the interval between
the diagnosis and the beginning of the treat-
ment, the higher the response for both pain and
function, particularly for patients with a dura-
tion of less than 5 years compared to patients
with a duration of 10 years or more. No other
criteria were found to be consistently associated
with the response to CS treatment.
Conclusion: The treatment of OA with CS has
the highest chance of success if administered in
the early stage of the disease. Further research
with other clinical outcomes should be carried
out prior to widespread application of these
findings.
Trial Registration: ClinicalTrials.gov identifier,
NCT03200288.
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Key Summary Points
In osteoarthritis, all patients are not
responsive to all interventions, so it is
important to define the profile of patients
who will best respond to a specific
intervention.
The use of prescription-grade
symptomatic slow-acting drugs for
osteoarthritis is proposed by some
guidelines.
The treatment of osteoarthritis with
chondroitin sulfate has the highest
chance of success if administered in the
early stage of the disease.
DIGITAL FEATURES
This article is published with digital features to
facilitate understanding of the article. You can
access the digital features on the article’s asso-
ciated Figshare page. To view digital features for
this article go to https://doi.org/10.6084/m9.
figshare.12776357.
INTRODUCTION
Osteoarthritis (OA) is the most common form of
arthritis worldwide and is associated with a
variety of symptoms, including pain, stiffness,
and reduced physical function. The alleviation
and control of symptoms is an important con-
sideration in the clinical practice of OA treat-
ments [1]. Many pharmacological and non-
pharmacological interventions are available,
and their effectiveness has been assessed in
numerous randomized controlled trials and in
expert reviews [2–5]. Recently, an update of the
treatment algorithm for the management of OA
by the European Society for Clinical and Eco-
nomic Aspects of Osteoporosis, Osteoarthritis
and Musculoskeletal Diseases (ESCEO) was also
published and provides practical guidance for
the prioritization of interventions [6]. In this
algorithm, the use of symptomatic slow-acting
drugs for osteoarthritis (SYSADOA) as the first-
line pharmacological therapy is proposed,
despite some controversies, as highlighted by
the non-recommendation of this class of drugs
by some international scientific societies [3, 5].
It should indeed be acknowledged that there are
many different agents in the class of SYSADOAs,
including glucosamine, chondroitin, diacerein,
and avocado soybean unsaponifiables, and not
all agents are supported with a high level of
clinical efficacy data [7]. Moreover, the quality
of the same agent could be different in a phar-
maceutical-grade product and an over the
counter one [8]. Regarding chondroitin sulfate
(CS), in a very recent meta-analysis, it was
shown that CS provides a moderate benefit for
pain and has a large effect on function but with
some inconsistency, explained by risks of bias,
brand, and study size [9].
Since it is widely acknowledged that all
patients are not fully responsive to all inter-
ventions, it is important to define the profile of
patients who will best respond to a specific
intervention. The aim of the present study is to
assess the responder profile of CS treatment
using the data collected during the CONCEPT
trial [10]. This was a prospective, randomized,
6-month, three-arm, double-blind, double-
dummy, placebo and celecoxib (200 mg/day)-
controlled trial assessing changes in pain and
physical function among 604 patients with
knee OA. In the study, it was shown that a CS
dose of 800 mg/day is superior to placebo and
similar to celecoxib in reducing pain and
improving function, confirming that this par-
ticular formulation of CS should be considered a
first-line treatment in knee OA management. In
that study, there was no significant difference
between CS, celecoxib, or placebo usage in the
rate of treatment-emergent adverse events,
serious adverse events, or adverse drug reac-
tions. The CS arm of this trial was then used to
investigate whether a responder profile to CS
could be defined.
METHODS
The present analysis is based on the CS arm of
the CONCEPT trial, a randomized controlled
trial (RCT) comparing the symptomatic effect of
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CS, celecoxib, and placebo in patients with knee
OA [10]. Briefly, this study included patients
over 50 years of age with primary knee OA
diagnosed according to the clinical and radio-
graphic criteria of the American College of
Rheumatology. Patients were randomly
assigned to one of the following three groups:
(1) CS group: one tablet of CS 800 mg and one
capsule of placebo celecoxib; (2) celecoxib
group: one tablet of placebo CS and one capsule
of celecoxib 200 mg; (3) placebo group: one
tablet of placebo CS and one capsule of placebo
celecoxib. All treatments were taken once daily,
every evening with a glass of water, for
6 months. In the CONCEPT study, there were
two co-primary endpoints. One primary end-
point was the change between baseline and
month 6 in the patient’s pain on a 100-mm
visual analogue scale (VAS). The other primary
endpoint was the change in the Lequesne index
(LI), which integrates pain and function. Sec-
ondary endpoints included the proportion of
patients reaching 20%, 40%, or 50% of minimal
clinically important improvement (MCII), the
patient acceptable symptom state (PASS), and
the Outcome Measures in Rheumatology
(OMERACT-OARSI) criteria [11–13].
The analysis was performed on the inten-
tion-to-treat (ITT) population, defined as all
randomized patients who received one dose of
the study medication. The results were expres-
sed as the means and standard deviations
(± SDs) for quantitative variables with a normal
distribution and as medians and interquartile
range (Q1–Q3) otherwise. Categorical variables
were expressed using numbers and percentages.
Values of VAS and LI measured at baseline and
after 6 months were compared by Wilcoxon
signed-rank test. The nonparametric
Kruskal–Wallis (KW) test was applied to com-
pare the VAS evolutions between subgroups,
and the Dwass, Steel, Critchlow, Fligner (DSCF)
procedure was used to compute multiple com-
parisons. The same statistical scheme was
applied to the LI evolution. The impact of var-
ious covariates (i.e., age, body mass index, sex,
Kellgren and Lawrence, time from diagnosis of
knee OA, and baseline level of VAS/LI) on the
VAS or LI evolution was assessed by means of
multiple regression; first for each covariate
separately in a univariate model and then for all
covariates combined in a multivariate model.
The analysis of variance (ANOVA) or the non-
parametric KW test was applied when appro-
priated to compare the different continuous
parameters according to various responder def-
initions. For qualitative parameters, a chi-
square test was used. The impact of the covari-
ates (i.e., age, body mass index, sex, Kellgren
and Lawrence, time from diagnosis of knee OA,
and baseline level of VAS/LI) on each responder
definition was assessed by means of a binary
logistic regression; first for each covariate sepa-
rately in a univariate model and then for all
covariates combined in a multivariate model.
All tests were two-sided, and the results were
considered statistically significant at the 5%
critical level (p\0.05). Statistical calculations
were carried out using the SAS statistical soft-
ware package (version 9.4 for Windows).
All participating centers of the CONCEPT
trial received ethics committee approval, the
study was performed in accordance with the
Declaration of Helsinki, and all patients pro-
vided their informed consent to participate.
RESULTS
Of the 604 patients randomized in the study,
199 received CS. In this group, the mean (SD)
age was 65.5 (8.0) years, the body mass index
was 30.2 (4.7) kg/m2, the time from diagnosis of
knee OA was 72.3 (69.2) months, and 78.34%
were female.
After 6 months of CS treatment, a decrease of
35.8 (26.8) mm on the VAS was observed. The
time from diagnosis of knee OA was the only
significant variable associated with the VAS
evolution (p\0.001) using multiple regression
analysis; no significant effect of age (p = 0.48),
body mass index (p = 0.92), sex (p = 0.46),
Kellgren and Lawrence (p = 0.52), or VAS pain
level at baseline (p = 0.12) was observed.
Patients with the shortest time since the diag-
nosis of OA experienced the largest improve-
ment of pain on the VAS (Fig. 1). In fact, a
decrease of 39.6 (25.9) mm was observed in
patients with a time since the OA diagnosis of
less than 5 years compared to a decrease of 24.7
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(27.2) points in patients with a diagnosis time
of more than 10 years (p\ 0.01). Table 1 shows
the clinical characteristics of the population
according to time from diagnosis.
At the end of the study, a decrease of 4.09
(3.74) points on the LI was observed in the CS
group. In the multiple regression analysis, only
the time since the diagnosis of OA and the LI at
baseline were significantly associated with the
LI change observed over the 6 months (both
p\0.001). Other variables such as age
(p = 0.60), body mass index (p = 0.97), sex
(p = 0.44), and Kellgren and Lawrence (p = 0.22)
were not associated with LI change. Patients
with less than 5 years since OA diagnosis expe-
rienced a median LI change of 4.50 points
compared to 3.75 points for those with a diag-
nosis time between 5 and 10 years and 1.5
points for those with a diagnosis time over
10 years (p\0.05). In patients with a baseline
LI of less than 12, the median improvement
was 3.50 points compared to 5.25 points for
subjects with LI of 12 or more (p\ 0.01).
Regardless of the definition that the respon-
ders considered (i.e., a 20% VAS MCII, a 40%
VAS/LI MCII, a 50% VAS/LI MCII, the PASS or
OMERACT-OARSI criteria), all univariate and
multivariate analyses provided the same results:
time since the diagnosis of OA is the only vari-
able significantly associated with the response
to the treatment. This means that the LI score at
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Fig. 1 Changes in the 100-mm visual analogue scale
(VAS) after 6 months of chondroitin sulfate treatment
according to the time from the diagnosis of knee
osteoarthritis
Table 1 Comparison of clinical characteristics of the study population according to time from diagnosis
Characteristics Diagnosis < 5 years Diagnosis 5–10 years Diagnosis > 10 years p value
Age, years 65 (59–69) 66 (59–74) 68 (63–73) 0.04*
Gender 0.39 ***
Male 32 (24.4) 4 (14.8) 7 (17.1)
Female 99 (75.6) 23 (85.2) 34 (82.9)
Body mass index, kg/m2 29.6 ± 4.7 32.8 ± 4.7 30.3 ± 3.9 0.004**
Kellgren–Lawrence grade 0.02***
1 34 (25.9) 9 (33.4) 5 (12.2)
2 67 (51.2) 13 (48.1) 20 (48.8)
3 30 (22.9) 4 (14.8) 16 (39.0)
4 0 (0) 1 (3.7) 0 (0)
VAS, 0–100 71 (64–78) 71 (62–76) 71 (64–78) 0.58*
Lequesne, 0–24 11.5 ± 2.8 12.2 ± 3.5 12.4 ± 2.9 0.18**
Continuous data are presented as mean ± standard deviation when normally distributed or median (P25–P50) when
skewed; categorical data are presented as absolute and relatives frequencies, N (%)
*Kruskal–Wallis (nonparametric) test, skewed variables
**ANOVA (parametric), Gaussian distribution
***Chi2 test, categorical data
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probability of responding to the treatment. Of
the 136 patients in the CS subgroup that had
experienced an MCII of at least 20% on the VAS,
63.2% had a time since the diagnosis of less
than 5 years, 24.3% between 5 and 10 years, and
12.5% over 10 years (p\ 0.01). Similar results
were observed when the OMERACT-OARSI cri-
teria were considered: of the 132 patients who
fulfilled these criteria, 65.9% had a time since
the diagnosis of less than 5 years, 22.0% had a
time between 5 and 10 years, and 12.1% had a
time over 10 years (p\ 0.01).
DISCUSSION
In the present study, we have shown that in
patients receiving CS for 6 months, the highest
improvement of pain and function was
observed in patients with the shortest time
since the diagnosis of osteoarthritis. These
results have been observed regardless of the
statistical methods used. To the best of our
knowledge, this is the first time that a responder
profile is proposed for the management of knee
OA with CS. With one other SYSADOA, some
similarities were observed. In fact, it was shown
that patients with less severe structural knee OA
(i.e., joint space width) experienced, over
3 years, the most dramatic disease progression
(i.e., joint space narrowing) but that the use of
the pharmaceutical-grade crystalline glu-
cosamine sulfate was able to partially avoid this
natural progression of the disease, while no
structural effect of the treatment was observed
in more severe patients [14]. Unfortunately, in
that particular study, no assessment of response
to the symptoms was performed. These results
suggest that SYSADOAs, or at least the phar-
maceutical-grade chondroitin and glucosamine
sulfate, provide a better effect when given in the
early stage of the disease. Few studies have been
performed with other pharmacological or non-
pharmacological interventions. For example,
the predictors of the response to the nons-
teroidal anti-inflammatory drug (NSAID) rofe-
coxib were age of the patient, their obesity
status, and the presence of concomitant dis-
eases (e.g., depression or diabetes mellitus) [15].
During rehabilitation, the predictor of response
included sex, presence of depression or comor-
bidities, and the use of complementary medi-
cine [16].
It should also be noted that our results were
consistent regardless of which definition of
response to treatment was used. In this partic-
ular study, and in accordance with the primary
study, we have used the most common defini-
tion, i.e., the MCII, the PASS, and the OMER-
ACT-OARSI criteria, as proposed by a group of
experts [17]. It is indeed important to place
additional emphasis on patients’ perceptions of
their clinical status in clinical trials and in
clinical practice.
In our initial analyses, we observed the
highest improvement in function in patients
with the highest LI at baseline. However, these
results were not confirmed in all of our statis-
tical analyses, especially when different defini-
tions of responders (i.e., MCII, PASS,
OMERACT-OARSI) were taken into account. It
seems quite reasonable to assume that the
absolute change in the LI has the greatest
probability of improving when the score is high
at baseline. Consequently, the interpretation
should be made with caution, even if some
adjustment was performed in the analysis.
However, it is interesting to note that, accord-
ing to the most recent meta-analysis, CS seems
to have a larger effect on function than on pain
[9].
We believe that these results re-emphasize
the importance of SYSADOAs as the first-line
treatment in the pharmacological management
of knee OA, as suggested by the recent update of
the ESCEO algorithm [6]. Of course, education
of the patient, promotion of physical activity,
and referral to a physical therapist are the very
first options of OA management and should be
encouraged. However, when non-pharmaco-
logical management is no longer sufficient to
restrain OA symptoms, given the limited
symptomatic effect of paracetamol and the
recent concerns over its safety profile in routine
chronic use [6], SYSADOAs could then be used
to initiate background therapy. This point of
view is consolidated by the excellent safety
profile of most of these SYSADOAs, especially
chondroitin sulfate, as acknowledged in a very
recent meta-analysis [18].
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We should acknowledge some limitations of
this study. First, many covariates that could
potentially influence the response to treatment
have not been taken into account (e.g., comor-
bidities, biological markers, psychological sta-
tus). However, our idea was to assess responder
criteria that are quite easily assessed in clinical
practice. The second limitation is that the
impact of compliance with the CS treatment
was not assessed in our analyses. We know that
compliance with treatment is a major public
health problem that could have an impact on
treatment effectiveness, and whether compli-
ance could have affected our results is
unknown. Third, the well-known placebo effect
could play an important role in the manage-
ment of OA and could then influence the
interpretation of our results, but its predictors
are currently not fully understood. One study
protocol aimed at the identification of predic-
tors of placebo response in OA using individual
patient data meta-analysis was published in
2016, but to the best of our knowledge, the
results are not yet available [19]. However, a
classical meta-analysis published in 2008
showed that the placebo effect was influenced
by the strength of the active treatment, the
baseline disease severity, the route of delivery,
and the sample size of the study [20]. Fourth,
some clinical data is missing (e.g. range of
motion, active knee flexion and extension,
WOMAC index) which could limit the gener-
alization of these results. Finally, our study was
conducted using prescription-grade CS, and
extrapolation could hardly be applied to other
formulations. Indeed, both the quality and the
quantity of chondroitin sulfate in food supple-
ments are highly heterogeneous [8], and con-
sequently, it has been highlighted that a
judicious choice of chondroitin formulation is
essential to maximize clinical benefit, patient
adherence, and satisfaction with treatment [21].
CONCLUSION
This formulation of CS reduces pain and
improves function over 6 months in a wide
range of patients with symptomatic knee OA.
However, the highest response to CS is observed
in patients with the shortest time between
diagnosis and initiation of therapy. Our data
highlight the importance of the early diagnosis
of osteoarthritis to optimize its management.
Indeed, when a pharmacological intervention is
needed to complement the non-pharmacologi-
cal treatments, CS could play an important role
as the first-line treatment of knee OA, especially
in the early stage of the disease.
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